High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
Systematic review of advancements and challenges in NK cell immunotherapy for malignancies
New NK cell therapies show promise for treating cancer
This systematic review evaluates Natural Killer (NK) cell immunotherapy, including CAR-NK, BiKEs, TriKEs, and CIML-NK cells, for hematologic…
New ways to use Natural Killer cells could help fight cancer while keeping the risk of dangerous immune reactions very low.
CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
CT scans may help predict lung cancer treatment response
This cohort study utilized a CT-based immune radiomic signature, known as CT-RadScore, across multiple patient cohorts including TCIA, TCGA,…
A new way to analyze CT scans could help doctors predict how lung cancer patients respond to immunotherapy and other drugs.
Review examines thoracic radiotherapy combined with chemoimmunotherapy for extensive-stage small cell lung cancer patients
Doctors are still figuring out the best way to treat extensive-stage small cell lung cancer.
This review examines the use of thoracic radiotherapy combined with chemoimmunotherapy in patients with extensive-stage small cell lung canc…
A review notes that while combining radiation with chemotherapy and immune therapy helps some patients, the best approach is still being stu…
Narrative review on ICIs in patients with viral infections and solid tumors
Cancer Immunotherapy Works Differently in Viral Infections
This narrative review synthesizes evidence on immune checkpoint inhibitors in patients with viral infections and solid tumors. It highlights…
Cancer immunotherapy can still work—and sometimes even control viruses like hepatitis or HIV—but doctors must watch for dangerous flare-ups.
Narrative review suggests time-related biases may attenuate apparent vaccine survival benefits in cancer patients.
New math shows vaccine benefits in cancer care might be overstated
This narrative review and target trial emulation examines 3-year overall survival in cancer patients receiving COVID-19 vaccines versus thos…
A new look at the data reveals that timing errors made the vaccine look more powerful than it actually is for cancer patients.
CIPHER model predicts immune checkpoint inhibitor pneumonitis risk in non-small cell lung cancer patients
Lung Scans Can Now Predict Dangerous Side Effect Before Treatment
This cohort study evaluated a CIPHER model versus classical radiomic models for predicting immune checkpoint inhibitor-induced pneumonitis i…
This tool could help doctors protect patients before a serious side effect strikes.
Review of combination strategies for digestive system tumors including gastric and colorectal cancer
Unlocking New Ways to Beat Drug Resistance in Digestive Cancers
This review examines theoretical approaches to enhance efficacy in patients with digestive system tumors, including gastric, colorectal, and…
Researchers are finding better ways to combine treatments so drugs keep working longer.
Meta-analysis of real-world studies associates COVID-19 vaccination with improved survival in cancer patients on ICIs
Cancer Patients Live Longer After COVID Shots
This meta-analysis of real-world studies evaluated 4,929 cancer patients receiving immune checkpoint inhibitors to assess COVID-19 vaccinati…
It started with a question doctors couldn’t answer: *Should patients on powerful cancer drugs get the COVID vaccine?* Some worried the immun…
Review of multi-omics technologies supporting immune checkpoint inhibitor use in cancer patients.
New Data Helps Doctors Pick Better Cancer Treatments
This review examines the application of multi-omics technologies within cancer patients treated with immune checkpoint inhibitors. The autho…
Using many types of medical data helps doctors choose the right cancer drugs for each person.
Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma.
Triple therapy offers a 52% chance of living three years with advanced liver cancer.
This retrospective cohort study evaluated 270 patients with unresectable hepatocellular carcinoma receiving first-line triple therapy across…
Patients with advanced liver cancer receiving triple therapy had a 52% chance of surviving three years, offering new hope for those facing d…
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma.
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…